We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+14.82%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$3.38B
AUM Growth
-$1.44B
Cap. Flow
-$1.68B
Cap. Flow %
-49.61%
Top 10 Hldgs %
44.12%
Holding
72
New
14
Increased
22
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$82.8M
2
VST icon
Vistra
VST
+$60.1M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$53.7M
4
EXTR icon
Extreme Networks
EXTR
+$47M
5
FLR icon
Fluor
FLR
+$41.8M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$32.3M
2
GDRX icon
GoodRx Holdings
GDRX
+$24.8M
3
KOP icon
Koppers
KOP
+$22.5M
4
ARDX icon
Ardelyx
ARDX
+$18.8M
5
COOP
Mr. Cooper
COOP
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 47.6%
2 Technology 8.46%
3 Financials 7.86%
4 Industrials 6.07%
5 Materials 5.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OABI icon
51
OmniAb
OABI
$497M
$15.5M 0.46%
2,850,588
– –
GDRX icon
52
GoodRx Holdings
GDRX
$1.22B
$15M 0.44%
2,117,054
-3,755,752
-64% -$24.8M
ARDX icon
53
Ardelyx
ARDX
$1.03B
$13.3M 0.39%
1,816,585
-2,196,168
-55% -$18.8M
RVNC
54
DELISTED
Revance Therapeutics, Inc.
RVNC
$13.1M 0.39%
2,656,847
+1,195,373
+82% +$7.08M
CGEM icon
55
Cullinan Oncology
CGEM
$1.26B
$10.7M 0.32%
626,929
– –
HOWL icon
56
Werewolf Therapeutics
HOWL
$18.6M
$10.5M 0.31%
1,621,034
-314,323
-16% -$1.83M
MD icon
57
Pediatrix Medical
MD
$2.15B
$9.11M 0.27%
+908,600
New +$8.45M
TSAT icon
58
Telesat
TSAT
$934M
$8.18M 0.24%
959,764
– –
MYPS icon
59
PLAYSTUDIOS Inc
MYPS
$72.1M
$6.59M 0.19%
2,368,777
+407,593
+21% +$946K
SPRY icon
60
ARS Pharmaceuticals
SPRY
$601M
$6.53M 0.19%
639,203
– –
OPK icon
61
Opko Health
OPK
$1.04B
$5.92M 0.18%
+4,935,814
New +$4.94M
PTGX icon
62
Protagonist Therapeutics
PTGX
$9.84B
$5.73M 0.17%
+198,059
New +$5.39M
CRS icon
63
Carpenter Technology
CRS
$26.3B
$5.62M 0.17%
+78,661
New +$5.15M
BCYC
64
Bicycle Therapeutics
BCYC
$284M
$5.12M 0.15%
205,423
– –
TXMD icon
65
TherapeuticsMD
TXMD
$24.1M
$2.73M 0.08%
1,192,191
– –
XERS icon
66
Xeris Biopharma Holdings
XERS
$1.55B
$687K 0.02%
+310,959
New +$805K
VINC
67
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$591K 0.02%
5,844
-11,875
-67% -$750K
PCRX icon
68
Pacira BioSciences
PCRX
$945M
– –
-491,322
Closed -$16.6M
SPY icon
69
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
– –
-4,500,000
Closed -$2.14B
STRO icon
70
Sutro Biopharma
STRO
$353M
– –
-334,481
Closed -$14.3M
SILK
71
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-1,427,905
Closed -$17.5M
1 2
3

Similar funds

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
LAMI
Longview Asset Management (Illinois) Chicago, Illinois $9.56B AUM 25.94% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $9.56B AUM 21.2% 1-Year Est. Return

Rubric Capital Management (New York)'s Q1 2024 Portfolio in Review

As of Q1 2024, Rubric Capital Management (New York) held 72 positions worth $3.38B, down 30% from $4.82B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rubric Capital Management (New York) withdrew a net $1.68B in Q1 2024, closing 4 positions and reducing 16 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $17.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 28% a quarter earlier, followed by Technology and Financials.

Against the trend, Rubric Capital Management (New York) opened a new position in Vistra worth $84.6M.

  • Rubric Capital Management (New York)'s largest Q1 2024 buy was Vistra: 1,213,998 shares worth $84.6M.
  • Rubric Capital Management (New York) added most to QuidelOrtho in Q1 2024, an estimated $82.8M increase.
  • Rubric Capital Management (New York)'s biggest Q1 2024 reduction was Collegium Pharmaceutical, cutting an estimated $32.3M.
  • Rubric Capital Management (New York) fully exited Silk Road Medical, Inc. Common Stock in Q1 2024, selling an estimated $17.5M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 44% of its $3.38B portfolio in Q1 2024.
  • Rubric Capital Management (New York) opened 14 new positions and closed 4 in Q1 2024.
  • Rubric Capital Management (New York)'s portfolio value fell 30% quarter-over-quarter to $3.38B.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2024, filed 10 May 2024.